Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.

× No keyword cloud information.

10 in total

1. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors: Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal: Am J Respir Crit Care Med Date: 2005-09-08 Impact factor: 21.405

2. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.

Authors: Mary C White; Jacqueline P Tulsky; Ju Ruey-Jiuan Lee; Lisa Chen; Joe Goldenson; Joanne Spetz; L Masae Kawamura
Journal: J Correct Health Care Date: 2012-03-14

3. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors: R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal: Z Rheumatol Date: 2009-07 Impact factor: 1.372

4. Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin.

Authors: Allison B Taylor; Ekaterina V Kurbatova; J Peter Cegielski
Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240

10. Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.

Authors: Anik R Patel; Jonathon R Campbell; Mohsen Sadatsafavi; Fawziah Marra; James C Johnston; Kirsten Smillie; Richard T Lester
Journal: BMJ Open Date: 2017-09-15 Impact factor: 2.692

10 in total

Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.

1. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

2. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.

3. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

4. Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin.

5. The use of anti-tuberculosis therapy for latent TB infection.

Review 6. New approaches in the diagnosis and treatment of latent tuberculosis infection.

7. Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.

8. Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada.

9. Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.

10. Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.